Crizotinib product-specific bioequivalence guidance

This document provides product-specific guidance on the demonstration of the bioequivalence of crizotinib.

Keywords: Bioequivalence, generics, crizotinib

Abbreviations:

• BCS Classification: Biopharmaceutics Classification System
• AUC_0-t: area under the plasma concentration curve from administration to last observed concentration at time t
• AUC_0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
• C_max: maximum plasma concentration

Current effective version

Crizotinib hard capsules 200 mg and 250 mg product-specific bioequivalence guidance

AdoptedReference Number: EMA/CHMP/805479/2016Legal effective date: 01/01/2018

Document history

Draft Crizotinib hard capsules 200 mg and 250 mg product-specific bioequivalence guidance

Draft: consultation closedConsultation dates: 22/12/2016 to 31/03/2017Reference Number: EMA/CHMP/805479/2016Summary:

This document provides product-specific guidance on the demonstration of the bioequivalence of Crizotinib